{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:24:02Z","timestamp":1787664242151,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10147-026-03120-0","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:03:25Z","timestamp":1784631805000},"page":"1735-1741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasone"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-2606","authenticated-orcid":false,"given":"Takeshi","family":"Aoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-454X","authenticated-orcid":false,"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Iino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Akechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyo K.","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Satomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako Eguchi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"3120_CR1","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"3120_CR2","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"key":"3120_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdz138","volume":"30","author":"K Jordan","year":"2019","unstructured":"Jordan K, Jahn F, Aapro M (2019) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 30:1081\u20131090. https:\/\/doi.org\/10.1093\/annonc\/mdz138","journal-title":"Ann Oncol"},{"key":"3120_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a010548","volume":"7","author":"AM Griffin","year":"1996","unstructured":"Griffin AM, Butow PN, Coates AS et al (1996) On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189\u2013195. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a010548","journal-title":"Ann Oncol"},{"key":"3120_CR5","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2026","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P et al (2026) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478. https:\/\/doi.org\/10.1200\/JCO.2006.05.6382","journal-title":"J Clin Oncol"},{"key":"3120_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103\u2013109. https:\/\/doi.org\/10.1200\/JCO.1997.15.1.103","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"3120_CR7","doi-asserted-by":"publisher","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232\u2013v243. https:\/\/doi.org\/10.1093\/annonc\/mdq194","journal-title":"Ann Oncol"},{"key":"3120_CR8","unstructured":"National Comprehensive Cancer Network (2023) NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 2. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1415. Accessed 23 March 2026"},{"key":"3120_CR9","doi-asserted-by":"publisher","first-page":"e71079","DOI":"10.1002\/cam4.71079","volume":"14","author":"J Bae","year":"2025","unstructured":"Bae J, Park JH, Kim YS et al (2025) Efficacy and safety of a 3-weekly TS-1 adjuvant regimen in advanced gastric cancer: a pilot study. Cancer Med 14:e71079. https:\/\/doi.org\/10.1002\/cam4.71079","journal-title":"Cancer Med"},{"key":"3120_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J et al (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011\u20131015. https:\/\/doi.org\/10.1038\/sj.bjc.6603048","journal-title":"Br J Cancer"},{"key":"3120_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2152\/jmi.61.86","volume":"61","author":"Y Ito","year":"2014","unstructured":"Ito Y, Tsujino K, Nozaki M et al (2014) Risk factors for dexamethasone-induced hyperglycemia in patients with hematological malignancies. J Med Invest 61:86\u201390. https:\/\/doi.org\/10.2152\/jmi.61.86","journal-title":"J Med Invest"},{"key":"3120_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/07853890902887054","volume":"41","author":"RL Oehler","year":"2009","unstructured":"Oehler RL, Patel P, Sharma M et al (2009) Risk of upper gastrointestinal bleeding associated with systemic corticosteroid use. Ann Med 41:447\u2013453. https:\/\/doi.org\/10.1080\/07853890902887054","journal-title":"Ann Med"},{"key":"3120_CR13","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/jbmr.4367","volume":"36","author":"CM Stevenson","year":"2021","unstructured":"Stevenson CM, Zhao LP, Liang F et al (2021) Fracture risk following corticosteroid use: a systematic review and meta-analysis. J Bone Min Res 36:1753\u20131764. https:\/\/doi.org\/10.1002\/jbmr.4367","journal-title":"J Bone Min Res"},{"key":"3120_CR14","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.4065\/81.10.1361","volume":"81","author":"TP Warrington","year":"2006","unstructured":"Warrington TP, Bostwick JM (2006) Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 81:1361\u20131367. https:\/\/doi.org\/10.4065\/81.10.1361","journal-title":"Mayo Clin Proc"},{"key":"3120_CR15","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1200\/JCO.1998.16.4.1568","volume":"16","author":"RJ Gralla","year":"1998","unstructured":"Gralla RJ, Navari RM, Hesketh PJ et al (1998) Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 16:1568\u20131573. https:\/\/doi.org\/10.1200\/JCO.1998.16.4.1568","journal-title":"J Clin Oncol"},{"key":"3120_CR16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","volume":"17","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441\u20131449. https:\/\/doi.org\/10.1093\/annonc\/mdl137","journal-title":"Ann Oncol"},{"key":"3120_CR17","first-page":"1059","volume":"11","author":"A Aleyasin","year":"2012","unstructured":"Aleyasin A, Hanafi S, Saffarieh E et al (2012) Efficacy of generic granisetron vs Kytril\u00ae for PONV in major gynecological operations: a randomized, double-blind clinical trial. Iran J Pharm Res 11:1059\u20131064","journal-title":"Iran J Pharm Res"},{"key":"3120_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3120_CR19","volume-title":"Minds handbook for clinical practice guideline development 2017","author":"Minds Guideline Center","year":"2017","unstructured":"Minds Guideline Center (2017) Minds handbook for clinical practice guideline development 2017. Japan Council for Quality Health Care, Tokyo"},{"key":"3120_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12016-014-8416-0","volume":"49","author":"M Picard","year":"2015","unstructured":"Picard M, Castells MC (2015) Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allergy Immunol 49:177\u2013191. https:\/\/doi.org\/10.1007\/s12016-014-8416-0","journal-title":"Clin Rev Allergy Immunol"},{"key":"3120_CR21","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.21873\/anticanres.15154","volume":"41","author":"K Ohata","year":"2021","unstructured":"Ohata K, Fujii H, Sadaka S et al (2021) Comparison of chemotherapy-induced nausea and vomiting between gemcitabine plus nab-paclitaxel combination chemotherapy and gemcitabine monotherapy in patients with advanced pancreatic cancer. Anticancer Res 41:3643\u20133648. https:\/\/doi.org\/10.21873\/anticanres.15154","journal-title":"Anticancer Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03120-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03120-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03120-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:08:41Z","timestamp":1787663321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03120-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3120"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03120-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the formatting of the funding statement.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hirotoshi Iihara received honoraria from Taiho Pharmaceutical Co., Ltd. Tatsuo Akechi has received lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Kowa Co., Ltd., Lundbeck Japan K.K., MSD K.K., Meiji Seika Pharma Co., Ltd., Merck Biopharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Tsumura & Co., UCB Japan Co., Ltd., and Viatris Inc.; a grant from Shionogi & Co., Ltd.; and royalties from Igaku-Shoin, outside the submitted work. TA also serves as the representative director of the General Incorporated Association NCU CRESS and receives compensation as an advisor to Snom Inc. TA has pending patents (2020-135195, 2024-516288, and 2025-128748) and a granted patent (7313617), all assigned to his institution. Chiyo K. Imamura received research funding from Otsuka Pharmaceutical Co., Ltd. Eriko Satomi received honoraria from Shionogi & Co., Ltd. Masayuki Takeda received honoraria from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Bristol Myers Squibb K.K., Janssen Pharmaceutical K.K., and Ono Pharmaceutical Co., Ltd. Takako Eguchi Nakajima received research funding from IQVIA Solutions Japan K.K., Thermo Fisher Scientific, Immunohelix, Ono Pharmaceutical Co., Ltd., BTB Therapeutics, Toregem BioPharma Co., Ltd., Advanced Accelerator Applications International, and Imel Therapeutics. Narikazu Boku received honoraria from Astellas Pharma Inc., Bristol Myers Squibb K.K., Taiho Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K., and research funding from Pfizer Inc. Koji Matsumoto received honoraria from MSD K.K., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd.; and research funding from Daiichi Sankyo Co., Ltd., MSD K.K., Gilead Sciences, Inc., and Eli Lilly Japan K.K. Nobuyuki Yamamoto received honoraria from MSD K.K., AstraZeneca K.K., AbbVie GK, Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., JAPAC, GlaxoSmithKline K.K., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Tsumura & Co., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Novocure Ltd., Pfizer Japan Inc., Merck Biopharma Co., Ltd., Janssen Pharmaceutical K.K., and Regeneron: Science of Medicine; research funding from MSD K.K., AstraZeneca K.K., AbbVie GK, Amgen K.K.,GlaxoSmithKline K.K., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Novocure Ltd., Parexel International Inc., Bristol Myers Squibb K.K., Medpace Japan K.K., Mebix, Inc., and Janssen Pharmaceutical K.K.; and scholarship donations from Nippon Kayaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Kyowa Kirin Co., Ltd. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (systematic review of published literature).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}